Structure-based optimization of tyrosine kinase inhibitors: a molecular docking study
- 8 Downloads
The most common pharmacologic approaches to inhibiting EGFR have been to develop small-molecule inhibitors which exert their effects at the intracellular portion of the receptor to prevent tyrosine kinase phosphorylation and subsequent activation of signal transduction pathways. A non-covalent molecular docking study was carried-out between 119 NCI anticancer compounds with receptor tyrosine kinase domain from epidermal growth factor receptor (PDB ID: 1M14), out of which 11 compounds had binding energy calculated with monte Carlo algorithm in ICM-pro Molsoft < − 25.25 kcal/mol. was found to have highest binding affinity with a reported value of − 32.832 kcal/mol, while Asaley had the overall least value (− 1.977 kcal/mol). The binding energy of all the compounds were found to be greatly influenced by the number and type of hydrogen bond interaction present between the ligands and the receptor except in few instances involving 5-flourouracil and mitomycin. A detailed description of the interactions of EGFR inhibitors developed can assist in the design of a more potent, more specific cytostatic drugs that can arrest tumor growth and cause tumor regression.
KeywordsNCI compounds Molecular docking Structure activity relationship (SAR) Binding affinity Hydrogen bond
The authors would like to thank Andrew Orry, for granting us the license for ICM-Pro molsoft program we adopted for this docking study.
- Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA (2002). Epidermal growth factor receptor family in lung cancer and premalignancy. In: Paper presented at the seminars in oncologyGoogle Scholar
- Hehre WJ, Huang WW (1995) Chemistry with computation: an introduction to SPARTAN: Wavefunction, Inc, IrvineGoogle Scholar
- MolSoft I (2000) 2.8 program manual. MolSoft LLC, San DiegoGoogle Scholar
- Petit A, Rak J, Hung M-C, Rockwell P, Goldstein N, Fendly B, Kerbel RS (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151(6):1523Google Scholar
- Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Gozzini A (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood 114(10):2168–2171CrossRefGoogle Scholar
- Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29(3):163–172CrossRefGoogle Scholar